Articles tagged with Hiv Vaccines
The NIH has launched a Phase 2b proof-of-concept study called Imbokodo to assess the safety and efficacy of an experimental HIV vaccine regimen. The study aims to enroll 2,600 HIV-negative women in sub-Saharan Africa and will test the quadrivalent mosaic vaccine against placebo.
Scientists at IAVI and TSRI published new findings on HIV-blocking antibodies, shedding light on their development and potential as a vaccine design. The research highlights the importance of understanding how neutralizing antibodies develop to create an optimal vaccine strategy.
Researchers tested a new vaccination approach in rhesus monkeys, finding that the type and order of administration influenced immune activation. The study showed promise for inducing sustained protective immunity without increasing CD4+ T helper cells.
A University of Maryland-led study developed a vaccine candidate that stimulates an immune response against the protective sugars of multiple HIV strains. The molecule mimics a protein-sugar part of the shield and spurs rabbits to produce antibodies, but does not prevent live HIV from infecting cells.
Despite progress in HIV treatment and prevention, a durable end to the pandemic may require an effective HIV vaccine. Existing tools such as antiretroviral therapy and pre-exposure prophylaxis can effectively prevent HIV transmission and manage the disease.
Researchers have found a way to generate long-lasting immune cells that can respond to and stop HIV virus infection. The team demonstrated that a modified gp140 protein approach improves B-cell responses, boosting the ability of B-cells to make protective antibodies against HIV.
An investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults, according to the APPROACH trial. The results support further development of candidate vaccines and plans for a larger trial in southern Africa to evaluate safety and efficacy.
Researchers at UNC are testing a therapeutic vaccine to target HIV reservoirs and boost the immune system's response. The goal is to potentially pair the vaccine with latency-reversing agents to clear the virus.
Researchers have developed an animal model using cows to elicit broadly neutralizing antibodies against HIV, which are difficult to achieve in humans. This breakthrough has the potential to accelerate the development of a more effective AIDS vaccine.
In a preclinical study, optimizing immunizations reliably elicits protective antibodies in non-human primates. Delivering the vaccine subcutaneously and increasing time intervals between immunizations improves efficacy and induces neutralizing antibodies.
A new study has shown that boosting volunteers with an additional dose of AIDSVAX B/E vaccine 6-8 years after their initial vaccination resulted in higher humoral and CD4+ T-cell responses. This increased immune response suggests a potential for improved protection against HIV infection.
A Duke-led research team developed an investigational vaccine that added three more targets to the original RV144 human vaccine candidate. The resulting pentavalent vaccine protected over half of the vaccinated animals from simian-human immunodeficiency virus infection, demonstrating improved protection compared to the original regimen.
A new Zika virus vaccine has shown 100% protection in mice, utilizing the NS1 protein. The vaccine's effectiveness was demonstrated through a single-dose immunization strategy.
Researchers at Scripps Research Institute have designed a mimic of the viral protein from a different HIV subtype, subtype C, to combat many strains of HIV. The new immunogen was tested in non-human primates and showed promising results in eliciting neutralizing antibodies.
A Canadian researcher has received a $3.99 million grant to develop an HIV vaccine candidate in partnership with IAVI. The team aims to improve upon a promising candidate and advance it to clinical testing in human volunteers.
Two new studies on DAR-901, a non-pathogenic bacterium-based vaccine, demonstrate improved protection against tuberculosis compared to the current BCG vaccine. The studies suggest that DAR-901 is likely to be as effective as the original formulation and may be the first protective TB vaccine in humans since BCG.
Professor Michael Farzan of Scripps Research Institute has received a $4.8 million grant to bring an HIV vaccine closer to human clinical trials. The project aims to develop an 'off switch' that halts production of antibodies and makes the vaccine safe for long-term exposure.
University of Nebraska-Lincoln researchers engineer an on/off switch into a weakened form of HIV to enhance vaccine safety and effectiveness. The team demonstrates that flipping the switch allows weakened HIV to replicate at a level likely to generate immunity in a host, while also allowing for controlled replication.
A vaccine with even partial effectiveness against HIV could prevent millions of new infections and potentially reverse the pandemic. However, diagnosis and treatment remain a significant challenge, particularly in high-risk groups.
A Duke Health-led research team has developed a synthetic HIV outer envelope mimic that induces broadly neutralizing antibodies with vaccination. The study supports the concept of designing vaccine candidates that mimic critical regions of HIV.
The HVTN 702 study is the largest and most advanced HIV vaccine clinical trial in South Africa, testing a new experimental vaccine regimen. The study aims to enroll 5,400 men and women and provide greater protection against HIV infection than previous vaccines.
A new approach to an HIV vaccine has been developed by combining a common cold virus with a DNA-based vaccine, resulting in specific immune responses in mice. The vaccine targets the Tat protein that helps the virus replicate, preventing infection and replication.
Researchers found that a therapeutic vaccine and immune stimulator combination improved virologic control and delayed viral rebound in non-human primates infected with SIV. The study showed promise for achieving long-term viral suppression without antiretroviral therapy.
Researchers developed a vaccine combining with an innate immune stimulant to target dormant HIV cells. The combination showed reduced viral loads and delayed rebound in animal trials, offering hope for ART-free, long-term viral suppression.
Researchers have developed a new approach to creating human vaccines against HIV using Kymouse, a genetically modified mouse that mimics human antibody responses. The study found that Kymouse can produce antibodies of the type needed for protection, suggesting ways to improve immunization regimes.
Researchers describe a potential vaccination strategy to jump-start the selection and evolution of broadly effective antibodies against HIV. They plan to test this approach in an upcoming human clinical trial, promising progress toward a human vaccine.
Researchers developed a technology to generate mouse models quickly testing and tweaking potential HIV vaccines. The goal is to create broadly neutralizing antibodies able to fight any mutant HIV strain, which would be the 'holy grail' of AIDS vaccines.
Scientists developed a reductionist approach to HIV vaccine design by engineering broadly neutralizing antibodies with minimized rare features. The resulting antibodies retained their specificity for HIV while exhibiting excellent neutralization breadth, offering promising leads for HIV vaccine development.
Researchers have successfully tested two Zika vaccine candidates in nonhuman primates, demonstrating robust protection against both Brazilian and Puerto Rican strains of the virus. The findings support the advancement of these vaccine candidates to human trials, with phase 1 clinical testing expected to begin later this year.
Researchers found that individuals with high levels of broadly neutralizing antibodies have distinct immune system variations, including autoantibodies and altered T follicular helper cells. These findings support approaches to developing an HIV vaccine by modifying the immune system to mimic these conditions.
Researchers at Duke University Medical Center have discovered key immune differences that can help in the development of an effective HIV vaccine. The study found that HIV-infected individuals with broadly neutralizing antibodies had similar immune alterations as those with autoimmune disease.
A promising TB vaccine candidate, Mtb Δppe25-pe19, induces a strong and diverse immune response to all mycobacterial PE/PPE proteins, offering insights into its protective efficacy. Unlike BCG, the new strain has an intact ESX-1 transport system, allowing it to induce phagosomal rupture and provoke innate immune responses.
Researchers are working on vaccines that induce broadly neutralizing antibodies to block a wide range of HIV variants, but the body does not readily make an adequate immune response to HIV infection. Efforts to vaccinate individuals with HIV immunogens have not yet been successful due to this issue.
A new study confirms the efficacy of the RV144 HIV vaccine in macaques, disproving the notion that a stronger adjuvant yields better results. The study found that changing the adjuvant did not improve the vaccine's effectiveness, but instead triggered an immune response at the site of infection.
Researchers at TSRI have advanced efforts to design an AIDS vaccine by stabilizing the HIV Envelope glycoprotein trimer and designing novel nanoparticles that mimic the virus. The stabilization strategy improves the protein's properties, allowing for the creation of HIV-like particles that can prompt the body to fight the real virus.
Researchers developed a new animal model to test HIV vaccines, combining the envelope of HIV with simian immunodeficiency virus to replicate in monkeys. Changing a single amino acid in the envelope coat protein improved the model's ability to infect monkeys while retaining native-like features.
A large clinical trial is set to begin in November 2016 to determine the safety and effectiveness of an investigational HIV vaccine regimen. The study, called HVTN 702, will enroll 5,400 adults at risk for HIV infection and assess the regimen's ability to prevent HIV infection among South African adults.
Researchers found that viral adaptation in HIV can predict a person's current disease status, as well as the degree to which newly transmitted HIV-1 is adapted to their new host. This knowledge can help design more effective vaccines by focusing on parts of the virus that are most difficult to undergo adaptation.
A preclinical study conducted by Texas Biomed has shown that Mymetics' HIV vaccine candidate generated significant protection in female monkeys, with an efficacy rate of 87%, delaying persistent infection after repeated viral challenges. The study's results suggest a potential breakthrough in developing an effective HIV vaccine.
The AMP study aims to assess the safety and efficacy of VRC01 in reducing HIV-1 acquisition among at-risk populations. The randomized, double-blind trial will enroll 2700 participants and follow them for up to 72 weeks.
Researchers at Vanderbilt University have isolated antibodies with a loop-like structure that binds tightly to HIV and disables it. The study suggests a new approach to rapidly induce broadly neutralizing antibodies in people who have not been exposed to HIV.
Researchers at TSRI have identified the first-ever immature HIV-neutralizing antibody, revealing a possible guide for developing an effective vaccine. The antibody, found in a Chinese patient, evolved rapidly and gained key traits within two years, contradicting previous theories.
A research team has found that engineered HIV proteins can bind key immune cells present in most people, which could lead to the development of a broadly neutralizing antibody-inducing vaccine. The study's findings provide an encouraging foundation for an upcoming clinical trial.
The study reveals the high-resolution structure of the HIV envelope protein, known as the Env trimer, in its natural form for the first time. The findings also include a detailed map of a vulnerable site at the base of this protein and the binding site of an antibody that can neutralize HIV.
A research team has identified rare potent antibodies in an HIV-infected individual and determined sequential structures that point to how they developed. This finding will help guide researchers as they try to build an experimental vaccine that recreates the pathway that gives rise to these important broadly neutralizing antibodies.
A European alliance, EHVA, has been granted 28 million Euros to develop novel preventive and therapeutic vaccines against HIV. The project aims to accelerate the development of innovative HIV vaccine concepts, focusing on prophylactic and therapeutic approaches.
Scientists at the University of Oxford have created a new technique to speed up vaccine development, utilizing isopeptide bonds to assemble vaccine candidates. This approach enables rapid production of stable vaccines with robust antibody responses.
A team of researchers at TSRI tracked the development of a family of antibodies that bind and neutralize HIV. By understanding how these antibodies evolve over time, scientists may be able to design a vaccine that triggers a faster immune response.
Researchers at The Scripps Research Institute have identified four prototype antibodies targeting a weak spot on HIV, which could lead to an effective vaccine. Two of these antibodies use their basic germline structure to bind with the virus, potentially allowing patients with HIV to kick-start a useful immune response.
A new €23 million initiative, EAVI2020, accelerates the search for an effective HIV vaccine by uniting leading researchers from across Europe and beyond. The project aims to develop protective and therapeutic vaccines through collaborative efforts.
A new review outlines findings that hint at the types of immune responses a preventive HIV vaccine may need to induce, including production of antiviral antibodies and CD4+ T cell responses. Many RV144 vaccinees produced antibodies in the IgG family linked to protection against acquiring HIV.
A recent study published in Nature Medicine has provided crucial insights for the development of a protective HIV vaccine. Researchers identified how changing viral swarms can drive the generation of antibodies able to neutralize diverse HIV strains worldwide.
A new study published in JAMA found that flu vaccination can prevent up to 57% of hospitalizations due to influenza pneumonia. The research used data from over 2,700 patients and showed that the vaccine not only prevents symptoms but also serious complications like pneumonia requiring hospitalization.
A study published in JAMA found that more than half of hospitalizations due to influenza pneumonia could be prevented by influenza vaccination. The study used data from 2,767 patients hospitalized with community-acquired pneumonia during three consecutive influenza seasons.
A UC Riverside-led study found a high prevalence of HPV infection among Peruvian men who have sex with men (MSM), highlighting the need for targeted HPV vaccine delivery. The study suggests that HPV vaccine can be a useful tool in preventing chronic infection and related cancers among sexually experienced individuals.
Researchers found that infection with multiple founder HIV-1 variants results in significantly higher mean viral loads and poorer clinical outcomes. The study analyzed data from two large HIV vaccine efficacy trials and showed that the number of variants at the beginning of infection affects the setpoint for viral load.
The HVTN 505 study found that the candidate vaccine induced polyreactive antibodies recognizing both HIV and intestinal microbes. These non-specific antibodies may decrease vaccine effectiveness against HIV.
The Scripps Research Institute has been awarded $4.5 million in grants from the Bill & Melinda Gates Foundation to support HIV vaccine development. The new funding will enable scientists to screen immunogens and vaccines with high likelihood of success.
Dr. Fauci emphasizes the need for targeted deployment of proven prevention methods to high-transmission areas, while also reviewing effective interventions such as ART, PrEP, and treatments that prevent mother-to-child HIV transmission.
The RV144 HIV vaccine trial found that host genetics influenced the immune response, with specific HLA alleles modulating antibody responses. This discovery could inform the development of more effective next-generation vaccines.